Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136869 | PMC |
| http://dx.doi.org/10.1016/j.annonc.2020.03.300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.
Front Immunol
January 2025
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
Introduction: Serum levels of interleukin-6 (IL-6) are increased in COVID-19 patients. IL-6 is an effective therapeutic target in inflammatory diseases and tocilizumab, a monoclonal antibody that blocks signaling via the IL-6 receptor (IL-6R), is used to treat patients with severe COVID-19. However, the IL-6R exists in membrane-bound and soluble forms (sIL-6R), and the sIL-6R in combination with soluble glycoprotein 130 (sgp130) forms an IL-6-neutralizing buffer system capable of neutralizing small amounts of IL-6.
View Article and Find Full Text PDFImmunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.
Immunotherapy
January 2025
Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul, Türkiye.
Hemophagocytic Lymphohistiocytosis (HLH) is a severe and potentially life-threatening condition characterized by an excessive and uncontrolled activation of the immune system. ICI-related hemophagocytic lymphohistiocytosis (irHLH) is a rare immune-related adverse event with an incidence of 0.03% to 0.
View Article and Find Full Text PDFAnti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.
ESMO Open
January 2025
Department of Medicine and DRCI, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.
Background: Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We report on the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS.
Patients And Methods: All 35 patients with solid cancers (sarcomas, lung carcinoma, and breast carcinoma) diagnosed with a PIS from 2019 to 2024 treated with tocilizumab were analyzed in this single-center study (health authorities' approval R201-004-478).
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records.
Rheumatol Adv Pract
December 2024
CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Article Synopsis
- The study explores factors influencing the start and stop of anti-IL-6 biologic DMARDs versus other bDMARDs in rheumatoid arthritis patients.
- It analyzed data from a Welsh health database, focusing on treatment initiation and outcomes like infections and hospitalizations.
- Findings show that anti-IL-6 bDMARDs were often chosen by patients with prior infections or kidney issues, and these patients had a lower treatment discontinuation rate compared to those on non-anti-IL-6 therapies.
Multicentric Castleman Disease: A Case Report of an Arab Female.
Cureus
October 2024
Department of Internal Medicine, University Hospital Sharjah, Sharjah, ARE.
We report the case of a 74-year-old female, who presented with a two-month history of fever, night sweats, and lymphadenopathy. She was thoroughly investigated, with high clinical suspicion for lymphoma. However, lymph node biopsy results revealed histopathological features of a hyaline vascular variant of Castleman disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!